Alcoholic hepatitis: Translational approaches to develop targeted therapies

Pranoti Mandrekar, Ramon Bataller, Hidekazu Tsukamoto, Bin Gao – 3 March 2016 – Alcoholic liver disease is a leading cause of liver‐related mortality worldwide. In contrast to recent advances in therapeutic strategies for patients with viral hepatitis, there is a significant lack of novel therapeutic options for patients with alcoholic liver disease. In particular, there is an urgent need to focus our efforts on effective therapeutic interventions for alcoholic hepatitis (AH), the most severe form of alcoholic liver disease.

Aspirin use and the risk of cholangiocarcinoma

Jonggi Choi, Hassan M. Ghoz, Thoetchai Peeraphatdit, Esha Baichoo, Benyam D. Addissie, William S. Harmsen, Terry M. Therneau, Janet E. Olson, Roongruedee Chaiteerakij, Lewis R. Roberts – 3 March 2016 – Whether aspirin use is protective against cholangiocarcinoma (CCA) remains unclear. We determined the association between aspirin use and other risk factors for each CCA subtype individually. In a hospital‐based case‐control study, 2395 CCA cases (1169 intrahepatic, 995 perihilar, and 231 distal) seen at the Mayo Clinic, Rochester, MN, from 2000 through 2014 were enrolled.

Platelets: No longer bystanders in liver disease

Abhishek Chauhan, David H. Adams, Steve P. Watson, Patricia F. Lalor – 2 March 2016 – Growing lines of evidence recognize that platelets play a central role in liver homeostasis and pathobiology. Platelets have important roles at every stage during the continuum of liver injury and healing. These cells contribute to the initiation of liver inflammation by promoting leukocyte recruitment through sinusoidal endothelium.

Severe alcoholic relapse after liver transplantation: What consequences on the graft? A study based on liver biopsies analysis

Domitille Erard‐Poinsot, Olivier Guillaud, Valérie Hervieu, Elsa Thimonier, Mélanie Vallin, Christine Chambon‐Augoyard, Olivier Boillot, Jean‐Yves Scoazec, Jérôme Dumortier – 1 March 2016 – Alcoholic liver disease (ALD) is a major indication for liver transplantation (LT), but up to 20% of patients experience severe alcoholic relapse. The aims of this study were to evaluate the impact of severe alcoholic relapse on the graft (based on histological examination) and to identify predictive factors associated with recurrent alcoholic cirrhosis (RAC).

The utility of pulmonary function testing in predicting outcomes following liver transplantation

Leila Kia, Michael J. Cuttica, Amy Yang, Erica N. Donnan, Maureen Whitsett, Ajay Singhvi, Alexander Lemmer, Josh Levitsky – 1 March 2016 – Although pulmonary function tests (PFTs) are routinely performed in patients during the evaluation period before liver transplantation (LT), their utility in predicting post‐LT mortality and morbidity outcomes is not known. The aim of this study was to determine the impact of obstructive and/or restrictive lung disease on post‐LT outcomes. We conducted a retrospective analysis of patients who had pre‐LT PFTs and underwent a subsequent LT (2007‐2013).

Preferential accumulation of T helper cells but not cytotoxic T cells characterizes benign subclinical rejection of human liver allografts

Anna K. Baumann, Jerome Schlue, Fatih Noyan, Matthias Hardtke‐Wolenski, Frank Lehner, Hannelore Barg‐Hock, Juergen Klempnauer, Michael P. Manns, Richard Taubert, Elmar Jaeckel – 1 March 2016 – Subclinical rejection (SCR) is a common event in protocol biopsies after liver transplantation (LT). So far the interpretation of the underlying histological changes and clinical significance is limited. Previous studies were restricted to SCR manifestations within the first weeks after transplantation with limited follow‐up.

Subscribe to